Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics

Collegium Pharmaceutical (COLL) reported $188 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 29.4%. EPS of $1.68 for the same period compares to $1.62 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $180.38 million, representing a surprise of +4.23%. The company delivered an EPS surprise of +3.7%, with the consensus EPS estimate being $1.62.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Total product revenues- Belbuca: $52.6 million versus the two-analyst average estimate of $54.94 million. The reported number represents a year-over-year change of +0.8%.Total product revenues- Xtampza ER: $52.61 million versus $48.28 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +18% change.Total product revenues- Jornay PM: $32.63 million versus the two-analyst average estimate of $32.23 million.Total product revenues- Nucynta: $46.45 million compared to the $43.31 million average estimate based on two analysts. The reported number represents a change of +4.4% year over year.Total product revenues- Symproic: $3.72 million versus $3.45 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.7% change.View all Key Company Metrics for Collegium Pharmaceutical here>>>Shares of Collegium Pharmaceutical have returned -8.1% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks